HER2-targeted Ab-PROTACs selectively degrade proteins in HER2-positive cancer cells, sparing healthy tissues in cancer therapy (Hu et al., 2022; Tsuchikama et al., 2024). This evidence concerns the gene ERBB2 and cancer.